John Libbey Eurotext

Bulletin du Cancer

MENU

Aromatase inhibitors: a review of clinical trials Volume 87, special issue 12, Numéro spécial, Décembre 2000

Figures

See all figures

Authors
Département d'oncologie médicale, Centre Eugène-Marquis, rue de la Bataille-Flandres-Dunkerque, CS 44229, 35042 Rennes Cedex.

To increase the therapeutic index of second line hormonal treatment of breast cancer, new aromatase inhibitors have been synthetized; they belong to two groups: type I (formestane and exemestane) are steroidal irreversible and specific inhibitors, type II (anastrozole, letrozole and vorozole) are non steroïdal reversible inhibitors, interfering with the aromatase heme. Several phase II and III trials demonstrated that these drugs are, at least, as active as aminoglutethimid or progestins in second line treatment, and are less toxic. Recently, an identical activity have been observed for anastrozole and tamoxifen in first line. In metastatic and adjuvant setting, large trials are ongoing to precise the exact value of these drugs.